5-7) Until the late 20th century, ocular hypertension
was included in the definition of human glaucoma.
LUMIGAN(TM) ophthalmic solution received FDA approval on March 16, 2001 and is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension
who are intolerant of other IOP-lowering medications or insufficiently responsive (failed to achieve target IOP determined after multiple measurements over time) to another IOP-lowering medication.
approval of RESCULA([R]) as a first-line agent for open-angle glaucoma or ocular hypertension
, and the news of its expected commercial market launch there.
5% administered twice daily (BID) in lowering IOP in patients with open-angle glaucoma or ocular hypertension
Pfizer's current product line includes the most prescribed treatment to lower elevated eye pressure in patients with ocular hypertension
(abnormally high eye pressure) or open-angle glaucoma.
Phase 3 Clinical Trial Pipeline Insights
Nearly half of patients who are prescribed eye drops to manage their ocular hypertension
do not refill their prescriptions after six months[sup.
The endpoint of the Phase IIa trial was to evaluate tolerance and the effect of a range of doses of the drug on 80 patients with ocular hypertension
or glaucoma in the three countries.
Trabodenoson is a first-in-class, highly selective A1 subtype adenosine mimetic for glaucoma and ocular hypertension
that binds to epithelial cells in the trabecular meshwork, up-regulating gelatinases that clean out and remodel the meshwork, increasing outflow and restoring a healthier IOP.
We believe that millions of patients with glaucoma and ocular hypertension
will benefit from the company's lead product candidate and we also see the potential to broaden the company's impact as it develops additional products.
Independently, pSivida is developing an injectable, sustained release product to treat uveitis affecting the back of the eye (posterior uveitis) and an injectable, bioerodible product to treat glaucoma and ocular hypertension
in collaboration with Pfizer.
The diagnosis of ocular hypertension
was one concern back then," he said, "the other plea we made was that there should be a wider range of tonometers allowable under the draft guidelines--when published the completed guidelines specifically only allowed slit-lamp mounted Goldmann tonometers.
a leader in the development of innovative drug candidates to address significant diseases of the eye, today announced that final data from a Phase 2 clinical trial of trabodenoson, also known as INO-8875, in patients with primary open-angle glaucoma or ocular hypertension
will be presented at the Ophthalmology Innovation Summit on Thursday, November 8, 2012 at the Chicago Marriott Downtown Magnificent Mile in Chicago, IL.
20, 2012 /PRNewswire/ -- Following encouraging results from Ocular Therapeutix's travoprost punctum plug feasibility study, the company is now entering a pilot Phase II clinical trial to examine a two-month sustained release drug (OTX-TP2) for the treatment of ocular hypertension
The Company currently has three product candidates in clinical development: ACU-4429 for dry age-related macular degeneration, rebamipide for dry eye syndrome and OPA-6566 for ocular hypertension
and glaucoma, all of which are being co-developed in the United States with Otsuka Pharmaceutical.